Maven Securities’s Astria Therapeutics ATXS Stock Holding History

Maven Securities’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,578	Closed	-$1.83M	–	404
2025 Q4	$1.83M	Buy	+139,578	New	+$1.67M	0.04%	322

Maven Securities's ATXS Position: Q1 2026 in Review

Maven Securities sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 139,578 shares — an estimated $1.83M sold.

Maven Securities first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $1.83M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Maven Securities reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Maven Securities sold 139,578 Astria Therapeutics shares in Q1 2026, an estimated $1.83M.
Maven Securities first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Maven Securities's Astria Therapeutics position peaked at $1.83M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.